13.2
Drug Dosing: Obese Patients
View the full transcript and gain access to JoVE Core videos
Q1: How is obesity defined in clinical practice?
Obesity is defined as actual body weight exceeding ideal body weight by 20% or more, based on Metropolitan Life Insurance Company data. Body mass index (BMI) is commonly used to classify obesity and correlates strongly with total body fat. BMI serves as a surrogate measure for assessing body composition in obese patients.
Q2: Why does obesity affect the apparent volume of drug distribution?
Obese patients have excess body fat and a smaller proportion of total body water compared to lean tissue. Since adipose tissue contains less water than muscle tissue, the apparent volume of drug distribution changes significantly. This altered distribution directly influences how drugs spread throughout the body and affects dosing requirements.
Q3: How should polar drugs like gentamicin be dosed in obese patients?
Polar drugs such as gentamicin distribute preferentially into lean tissue and extracellular fluids rather than adipose tissue. These drugs should be dosed based on ideal body weight rather than total body weight to avoid overdosing. Using ideal body weight ensures appropriate drug concentrations without excessive accumulation.
Q4: What dosing approach is used for non-polar drugs in obese patients?
Non-polar drugs like diazepam distribute more readily into adipose tissue than lean tissue. These drugs require larger doses based on the patient's total body weight to achieve therapeutic concentrations. The increased body fat in obese patients necessitates dose adjustments to account for greater drug partitioning into lipid environments.
Q5: How are amphiphilic drugs like lidocaine dosed differently?
Amphiphilic drugs such as lidocaine distribute equally between lean and adipose tissues. These drugs are dosed based on the patient's total body weight rather than ideal body weight. This approach accounts for their balanced distribution across both tissue types in obese patients.
Q6: What health complications are associated with obesity?
Obesity increases the risk of hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. These conditions significantly increase mortality rates in affected populations. Understanding these complications is essential for comprehensive patient care and appropriate drug dosing decisions in obese populations.
Q7: How do physiologic alterations in obesity affect drug metabolism and excretion?
Obesity may alter biotransformation and renal excretion, requiring nuanced drug dosing strategies. Changes in body composition affect how the body processes and eliminates drugs. These alterations necessitate careful consideration of pharmacokinetic parameters when determining appropriate doses for obese patients receiving medications.